- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06911619
Impact of Nutritional Management on the Frailty of Patients Waiting for Liver Transplantation (Via the LFI Tool) (LFI-PATH)
July 1, 2025 updated by: Hospices Civils de Lyon
Cirrhosis is a major public health issue responsible for about 15000 deaths each year.
Liver transplantation (LT) remains the only curative treatment for decompensated cirrhosis.
Decompensated cirrhotic patients awaiting LT are malnourished, sarcopenic and fragile.
The evaluation of the nutritional status of these patients is complex because the anthropometric data that define undernutrition (weight variation, BMI) are often compromised by the presence of edema and ascites related to liver disease.
It therefore seems appropriate to focus on the fragility and sarcopenia of the cirrhotic patient as a reflection of the nutritional status.
In 2017, the American team of Lai et al. validated a Liver fraily index (LFI) score of frailty specific to cirrhotic patients waiting for LT.
The LFI is composed of three simple physical tests (Grip test, chair lift test, and balance tests) performed at the patient's bedside, which results in a quantitative and reproducible frailty score.
Frailty while waiting for LT is associated with an increase in mortality on the waiting list, independently of the MELD (Model for End stage Liver disease) score, which is a reflection of liver severity.
About half of the patients who are candidates for LT will present an aggravation of their frailty while waiting for LT.
To date, no study has reported the results of a nutritional intervention on the evolution of fragility in patients awaiting LT.
The objective of our study is to evaluate the impact of a nutritional management and follow-up by a dietitian specialized in hepatology on the fragility of patients waiting for LT.
This is a monocentric study, randomized in two parallel groups (an intervention group with nutritional follow-ups by a trained dietitian and a control group with follow-up by the reference hepatologist without specific dietary management by a dietician) in open.
All patients enrolled on the LT list with an LFI > 3.2 (pre-frail and frail state) will be included in the study.
It is planned to include 210 patients over a period of 24 months.
The LFI will be measured for all patients (control group + intervention group) at 3 and 6 months, as part of their follow-up in the LT center.
This study will also make it possible to correlate frailty with other parameters (severity of liver disease, access to LT).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
210
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Maxime PATUREL, Diététicien, FF CDS
- Phone Number: +33 (0)4 72 07 25 43
- Email: maxime.paturel@chu-lyon.fr
Study Contact Backup
- Name: Mahutondji Calèbe SOMASSE
- Phone Number: +33 (0)4 72 07 13 36
- Email: mahutondji-calebe.somasse@chu-lyon.fr
Study Locations
-
-
-
Lyon, France, 69004
- Recruiting
- Hôpital de la Croix Rousse / GHN
-
Contact:
- Maxime PATUREL, Diététicien, FF CDS
- Phone Number: +33 (0)4 72 07 25 43
- Email: maxime.paturel@chu-lyon.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient aged ≥ 18 years
- Patient registered on the waiting list for Hepatic Transplantation in the Transplantation center of the Croix Rousse Hospital (GHN), Hospices Civils de Lyon
- Dated and signed an informed consent
- Affiliated to a social security scheme or beneficiary of a similar scheme
Exclusion Criteria:
- Patient hospitalized in intensive care
- Patient with initial LFI test result < to 3.2, that is considered as "robust".
- Patient unable to perform LFI exercises (chronic or acute motor disability in lower or upper limbs)
- Pregnant, parturient or lactating women
- Persons deprived of liberty by a judicial or administrative decision
- Persons under psychiatric care
- Persons admitted to a health or social institution for purposes other than research
- Adults subject to a legal protection measure (guardianship, curatorship)
- Inability to understand protocol information
- Subject participating in another interventional research including an ongoing exclusion period at inclusion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Dietary intervention Group
The intervention consists of a personalized dietary management with a nutritional follow-up pending transplantation.
Teleconsultation appointments are scheduled with the dietician for dietary coaching and a re-evaluation of the nutritional strategy.
Follow-up visits in person, carried out by the dietician at the 3rd and 6th month waiting for liver transplantation and are coupled with the usual consultations with the referring hepatologist.
The visits allow the realization of LFI (Liver Frailty Index), the collection of interrelated events and the reassessment of hepatic disease as well as the re-evaluation of the nutritional strategy (oral nutritional supplement, enteral or parenteral nutrition)
|
The intervention consists of a personalized dietary management with a nutritional follow-up pending transplantation.
Teleconsultation appointments are scheduled with the dietician for dietary coaching and a re-evaluation of the nutritional strategy every month.
Follow-up visits in person, carried out by the dietitian at the 3rd and 6th month waiting for transplant and are coupled with the usual consultations with the referring hepatologist.
The visits allow the realization of LFI (Liver Frailty Index), the collection of interrelated events and the reassessment of hepatic disease as well as the re-evaluation of the nutritional strategy (CNO, enteral or parenteral nutrition)
|
|
Other: Standard Follow up
The patient will be followed up by his referee hepatologist every 3 months.
The 3-month and 6-month follow-up visits pending transplantation will be performed with a Clinical Research Assistant on the same day as the follow-up consultation with his hepatologist with the completion of the LFI test and the collection of intercurrent events and the re-evaluation of the liver disease.
|
The patient will be followed up by his reference hepatologist every 3 months.
Follow-up visits at 3 months and 6 months waiting for liver transplantation will be performed by Clinical Research assistant on the same day as the follow-up consultation with his hepatologist with the completion of the Liver Frailty Index test and the collection of intercurrent events and the reassessment of liver disease.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the impact at 3 months, of a nutritional management and follow-up by a dietitian specialized in hepatology compared to the usual management without dietary follow-up, on the fragility of patients waiting for liver transplantation (LT).
Time Frame: 3rd month after visit 1.
|
Measurement of LFI (Liver fraily index) score score variation between D0 (baseline = visit 1) and 3 months (first reassessment = visit 2) during the liver transplantation waiting period.
This variation will be compared between the intervention group and the control group.
|
3rd month after visit 1.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the impact of a nutritional follow-up on the fragility of patients at 6 months on list
Time Frame: 6th Month after visit 1.
|
For patients still on the liver transplantation waiting list, comparison between the intervention and control group of the LFI (Liver fraily index) variation between Baseline (visit 1) and month 6 (visit 3).
|
6th Month after visit 1.
|
|
Evaluate the impact of a nutritional follow-up on the distribution of patients' frailty according to classes: robust, pre-fragile, fragile
Time Frame: 3rd Month (M3) after Visit 1 and M6 after V1
|
Compare the evolution of the fragility profile (Robust - Prefragile - Fragile) of patients waiting for liver transplantation according to LFI (Liver fraily index) at M3 and M6 in the intervention group and in the control, group compared with the initial LFI (D0)
|
3rd Month (M3) after Visit 1 and M6 after V1
|
|
Evaluate compliance with oral nutritional supplement treatment for patients awaiting transplant
Time Frame: 3rd Month and 6th month after Visit 1
|
At each follow-up visit (M3 and M6) assessment of compliance with oral nutritional supplements for patients who were prescribed oral nutritional supplements, through questioning their intake: 0, 1⁄4, 1⁄2, 3⁄4 or all of the oral nutritional supplements consumed compared to the prescription.
|
3rd Month and 6th month after Visit 1
|
|
Evaluate the relationship between fragility and severity of liver disease (MELD score)
Time Frame: Day 0, 3rd Month (M3) and 6th Month (M6)
|
Measure the correlation between LFI (Liver fraily index) at Day 0, M3 and M6 and the severity of liver disease (MELD score),
|
Day 0, 3rd Month (M3) and 6th Month (M6)
|
|
Evaluate the relationship between fragility and access to a transplant
Time Frame: Day 0, Month 3 after Visit 1, Month 6 after Visit 1
|
Measure the correlation between the LFI (Liver fraily index) score at Day 0, Month 3 and Month 6 and access to the transplant
|
Day 0, Month 3 after Visit 1, Month 6 after Visit 1
|
|
Evaluate the relationship between fragility and mortality on waiting list of transplantation or leaving the list due to worsening
Time Frame: Day 0, 3rd month and 6th month
|
Measure the correlation between LFI (Liver fraily index) score at Day0, M3 and M6 and on-list mortality or leaving the list due to worsening
|
Day 0, 3rd month and 6th month
|
|
Evaluate the relationship between frailty and unscheduled hospitalizations while waiting for Liver Transplantation
Time Frame: Day 0, 3rd month and 6th month after Visit 1
|
Measure the correlation with the LFI (Liver fraily index) score on Day 0, M3 and M6 and unscheduled hospitalizations awaiting transplant: numbers and indications (infections, encephalopathy, hemorrhage, etc.)
|
Day 0, 3rd month and 6th month after Visit 1
|
|
Evaluate the satisfaction of dieticians in carrying out nutritional monitoring for patients waiting for liver transplantation (logistics of organizing consultations and teleconsultations)
Time Frame: study completion at Month 30
|
Evaluate the satisfaction of dieticians in carrying out nutritional monitoring for patients waiting for Liver Transplantation (logistics of organizing consultations and teleconsultations) via questionnary
|
study completion at Month 30
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Maxime PATUREL, Service Rééducation Nutritionnelle Hôpital de la Croix Rousse / GHN
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 30, 2025
Primary Completion (Estimated)
June 30, 2027
Study Completion (Estimated)
December 30, 2027
Study Registration Dates
First Submitted
March 21, 2025
First Submitted That Met QC Criteria
March 28, 2025
First Posted (Actual)
April 4, 2025
Study Record Updates
Last Update Posted (Actual)
July 4, 2025
Last Update Submitted That Met QC Criteria
July 1, 2025
Last Verified
July 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL24_1201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cirrhosis
-
University Health Network, TorontoUnknown
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
Northwestern UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsActive, not recruitingCirrhosis | Autoimmune Hepatitis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
National Institute of Diabetes and Digestive and...National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis AlcoholicUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingPrimary Biliary CirrhosisChina
-
Indiana UniversityRecruiting
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingDecompensated CirrhosisIndia
-
Beijing 302 HospitalWuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, ChinaNot yet recruitingDecompensated CirrhosisChina
-
Xin ZengRecruitingDecompensated CirrhosisChina
-
Changi General HospitalRecruiting
Clinical Trials on Dietary management
-
Chen LiChildren's Hospital of Chongqing Medical University; China Soong Ching Ling...RecruitingOverweight and ObesityChina
-
Peking Union Medical College HospitalUnknownChronic Disease | Dietary FiberChina
-
Johns Hopkins UniversityCompletedEpilepsyUnited States
-
Gérond'ifRecruitingUndernutrition of Elderly PeopoleFrance
-
The University of Texas Health Science Center,...Completed
-
Peking Union Medical College HospitalNot yet recruiting
-
Xiamen UniversityRecruiting
-
Ji JingCompletedGestational Diabetes Mellitus (GDM)China
-
Korea University Anam HospitalThe Korean Vascular Research Working GroupCompleted
-
Capital Medical UniversityRecruitingGestational Diabetes Mellitus | Hypertensive Disorder of PregnancyChina